559 related articles for article (PubMed ID: 18691990)
1. In vitro stability of lyophilized and reconstituted recombinant activated factor VII formulated for storage at room temperature.
Nedergaard H; Vestergaard S; Jensen PT; Kristiansen MW; Jensen MB; Ostergaard PB; Norsell T; Bjerre J
Clin Ther; 2008 Jul; 30(7):1309-15. PubMed ID: 18691990
[TBL] [Abstract][Full Text] [Related]
2. In vitro stability of two formulations of recombinant activated factor VIIa reconstituted in inappropriate solvents or at inappropriate volumes.
Petersson B; Schönwandt AB; Thornstfeldt P; Nedergaard H; Jensen MB; Thornstergaard PB; Norsell T; Bjerre J
Clin Ther; 2008 May; 30(5):917-23. PubMed ID: 18555938
[TBL] [Abstract][Full Text] [Related]
3. Room-temperature-stable recombinant activated coagulation factor VII recombinant: chemical and microbiologic stability over 24 hours during continuous in vitro infusion.
Christensen A; Jensen JT; Nøhr AM; Cooper DL
Clin Ther; 2011 Dec; 33(12):1997-2001. PubMed ID: 22088413
[TBL] [Abstract][Full Text] [Related]
4. Effect of X-ray radiation exposure on lyophilized recombinant activated factor VII (formulated for storage at room temperature).
Vestergaard S; Nedergaard H; Jonasdottir O; Wagner Kristiansen M; Mette Nøhr A; Bjerre J
Curr Med Res Opin; 2009 Nov; 25(11):2699-702. PubMed ID: 19775196
[TBL] [Abstract][Full Text] [Related]
5. Stability Studies of a Freeze-Dried Recombinant Human Epidermal Growth Factor Formulation for Wound Healing.
Santana H; García G; Vega M; Beldarraín A; Páez R
PDA J Pharm Sci Technol; 2015; 69(3):399-416. PubMed ID: 26048746
[TBL] [Abstract][Full Text] [Related]
6. Stability of lyophilized and reconstituted plasma/albumin-free recombinant human factor VIII (ADVATE rAHF-PFM).
Parti R; Schoppmann A; Lee H; Yang L
Haemophilia; 2005 Sep; 11(5):492-6. PubMed ID: 16128893
[TBL] [Abstract][Full Text] [Related]
7. Long-term stabilization of a new freeze-dried and albumin-free formulation of recombinant human interferon alpha 2b.
Ruiz L; Reyes N; Sotolongo J; Aroche K; Aldana R; Báez R; Hardy E
PDA J Pharm Sci Technol; 2006; 60(1):72-8. PubMed ID: 17089680
[TBL] [Abstract][Full Text] [Related]
8. A randomized, double-blind trial demonstrating bioequivalence of the current recombinant activated factor VII formulation and a new robust 25 degrees C stable formulation.
Bysted BV; Scharling B; Møller T; Hansen BL
Haemophilia; 2007 Sep; 13(5):527-32. PubMed ID: 17880439
[TBL] [Abstract][Full Text] [Related]
9. Stability of doripenem in vitro in representative infusion solutions and infusion bags.
Psathas PA; Kuzmission A; Ikeda K; Yasuo S
Clin Ther; 2008 Nov; 30(11):2075-87. PubMed ID: 19108795
[TBL] [Abstract][Full Text] [Related]
10. Stability of Reconstituted Fibrinogen Concentrate in Hemostatic Function and Concentration.
Peng HT; Beckett A
Mil Med; 2021 Feb; 186(3-4):286-292. PubMed ID: 33196820
[TBL] [Abstract][Full Text] [Related]
11. Thermal stability and storage of human insulin.
Richter B; Bongaerts B; Metzendorf MI
Cochrane Database Syst Rev; 2023 Nov; 11(11):CD015385. PubMed ID: 37930742
[TBL] [Abstract][Full Text] [Related]
12. The Effect of High Storage Temperature on the Stability and Efficacy of Lyophilized Tenecteplase.
Henkel E; Vella R; Fenning A
Prehosp Disaster Med; 2020 Oct; 35(5):501-507. PubMed ID: 32686630
[TBL] [Abstract][Full Text] [Related]
13. Stability characterization and appearance of particulates in a lyophilized formulation of a model peptide hormone-human secretin.
Srinivasan C; Siddiqui A; Korang-Yeboah M; Khan MA
Int J Pharm; 2015 Mar; 481(1-2):104-13. PubMed ID: 25636302
[TBL] [Abstract][Full Text] [Related]
14. In vitro effect of activated recombinant factor VII (rFVIIa) on coagulation properties of human blood at hypothermic temperatures.
Kheirabadi BS; Delgado AV; Dubick MA; Scherer MR; Fedyk CG; Holcomb JB; Pusateri AE
J Trauma; 2007 Nov; 63(5):1079-86. PubMed ID: 17993954
[TBL] [Abstract][Full Text] [Related]
15. Feasibility of using recombinant factor VIIa in continuous infusion.
Schulman S; Bech Jensen M; Varon D; Keller N; Gitel S; Horoszowski H; Heim M; Martinowitz U
Thromb Haemost; 1996 Mar; 75(3):432-6. PubMed ID: 8701403
[TBL] [Abstract][Full Text] [Related]
16. B-domain deleted recombinant factor VIII formulation and stability.
Osterberg T; Fatouros A; Neidhardt E; Warne N; Mikaelsson M
Semin Hematol; 2001 Apr; 38(2 Suppl 4):40-3. PubMed ID: 11449334
[TBL] [Abstract][Full Text] [Related]
17. Pharmacokinetics and safety of a 270 mcg kg-1 dose of room temperature stable recombinant activated factor VII in patients with haemophilia.
Morfini M; Bjerre J
Haemophilia; 2011 Nov; 17(6):860-6. PubMed ID: 21371194
[TBL] [Abstract][Full Text] [Related]
18. In vitro stability studies of a Factor IX concentrate (Bebulin).
Dal Bo Zanon R; Gazzetta R; Patrassi G; Stocco D; Girolami A
Folia Haematol Int Mag Klin Morphol Blutforsch; 1983; 110(6):874-8. PubMed ID: 6200399
[TBL] [Abstract][Full Text] [Related]
19. Pharmacokinetics and pharmacodynamics of recombinant factor VIIa.
Lindley CM; Sawyer WT; Macik BG; Lusher J; Harrison JF; Baird-Cox K; Birch K; Glazer S; Roberts HR
Clin Pharmacol Ther; 1994 Jun; 55(6):638-48. PubMed ID: 8004880
[TBL] [Abstract][Full Text] [Related]
20. Stability of thiotepa (lyophilized) in 0.9% sodium chloride injection.
Murray KM; Erkkila D; Gombotz WR; Pankey S
Am J Health Syst Pharm; 1997 Nov; 54(22):2588-91. PubMed ID: 9397220
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
